Reata Pharmaceuticals Inc. (RETA) Has Jumped To A New High On Study Results

Reata Pharmaceuticals Inc. (RETA) reported positive results from its Phase 2 study of bardoxolone methyl in patients with chronic kidney disease Monday morning.

Reata Pharmaceuticals gapped open higher Monday and has continued to rise in early trade. Shares are now up 9.36 at $55.76 on above average volume. The stock has broken out to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Follow RTT